Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: A strong inverse correlation between BCL6 protein expression and EBV infection is found in a series of 149 DLBCL samples, where only one out of 34 EBV-positive cases (2.94%) expressed BCL 6, although 87 out of 115EBV-negative cases expressed B CL6 (75.65%).
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma, accounting for 30–40% of all newly diagnosed lymphomas. DLBCL is considered a heterogeneous disease, with some specific clinicopathological variants of DLBCLs being associated with the presence of the EBV.1 EBV is a lymphotropic virus that has been implicated in the development of several lymphoid malignancies, mainly Burkitt lymphoma (BL) and Hodgkin's lymphoma and with low prevalence in DLBCL.1 BCL6 is a key transcriptional repressor during normal B-cell differentiation that has been shown to repress NF-kB in some DLBCLs.2 In some B-cell lymphomas, BCL6 expression was inversely correlated with LMP1 expression, and some evidences suggest that LMP1 can cause downregulation of BCL6(ref. 3), but other possible mechanisms have not been studied. We have found a strong inverse correlation between BCL6 protein expression and EBV infection (P<0.001, Figures 1a and b) in a series of 149 DLBCL samples, where only one out of 34 EBV-positive cases (2.94%) expressed BCL6, although 87 out of 115 EBV-negative cases expressed BCL6 (75.65%). However, this correlation was independent of LMP1 because 54% of EBER-positive samples were LMP1-negative (Spearman, P-value: 0.18). Little is known about the mechanisms that cause the absence of BCL6 in EBV-positive DLBCL; however, the possibility that EBV-encoded miRNAs could contribute to BCL6 repression has never been explored.
47 citations
TL;DR: The biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET-amplification are assessed and new treatment strategies are proposed in this situation.
47 citations
TL;DR: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm.
47 citations
University of Sydney1, Harvard University2, Hebron University3, Samsung Medical Center4, Yale Cancer Center5, Princess Margaret Cancer Centre6, University of Pennsylvania7, Vanderbilt University8, University of Birmingham9, University of California, San Francisco10, Memorial Sloan Kettering Cancer Center11, Institut Gustave Roussy12, Emory University13, Merck & Co.14, University of California, Los Angeles15
TL;DR: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy.
Abstract: 9026Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This approval was based on da...
47 citations
University of Washington1, Institut Gustave Roussy2, Technische Universität München3, University of Wollongong4, Hebron University5, Auckland City Hospital6, St. Vincent's Health System7, University College London8, Macquarie University9, Curie Institute10, Merck & Co.11, The Royal Marsden NHS Foundation Trust12
TL;DR: Combination of pembro + olaparib has activity in pts previously treated with docetaxel and ≤2 2nd-generation HT for mCRPC and who are HRR wild type, and Observed safety profile for the combination is consistent with individual profiles of p embro and olapsarib.
Abstract: 145Background: Activity with pembro or olaparib has been observed in mCRPC pts who progressed on 2nd-generation hormonal therapy (HT) and chemotherapy. From KEYNOTE-365 (NCT02861573), a phase 1b/2 ...
47 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |